DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Prevention of Imminent Paralysis Following Spinal Cord Trauma or Ischemia by Minocycline: A Multi-center Study in Israel With IDF Primary Care Involvement

Information source: Hadassah Medical Organization
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Spinal Tumors, Trauma Patients, Minocycline.

Intervention: Minocycline (Drug); placebo (Drug)

Phase: Phase 2/Phase 3

Status: Not yet recruiting

Sponsored by: Hadassah Medical Organization

Overall contact:
Benjamim Drenger, Prof., Email: drenger@ekmd.huji.ac.il

Summary

Spinal cord trauma and the consequent paraplegia are possibly among the most devastating injuries in soldiers and during spine surgery, and are significant in the medical, social and financial aspects. Limited mobility, the need for assistance in all human activities, shame, and many medical complications related directly to the neural deficits make paraplegia an important target for prevention. Our study will evaluate the efficacy of Minocycline in two different groups: 1. Minimizing the neurological damage among trauma patients. 2. Preventing neurological damage through operation in spinal tumors patients. 2. OBJECTIVES The primary objectives of the trial are to determine: 1. Efficacy of administrating minocycline in minimizing the neurological damage among acute spinal cord injury patients and spinal cord tumors (primary and metastases) patients? 2. Efficacy of administrating minocycline at changing the natural history and rehabilitation of spinal cord trauma patients. 3. Safety of applying minocycline in spinal cord injuries patients and spinal cord tumors?

Clinical Details

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention

Primary outcome: Efficacy of administrating minocycline in minimizing the neurological damage among acute spinal cord injury patients and spinal cord tumors (primary and metastases) patients

Secondary outcome:

Efficacy of administrating minocycline at changing the natural history and rehabilitation of spinal cord trauma patients.

Safety of applying minocycline in spinal cord injuries patients and spinal cord tumors?

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria: Trauma patients with incomplete spinal cord syndromes related to fractures, dislocations, blunt trauma (central cord syndrome). 1. Inclusion Criteria: 2. Patients with incomplete spinal cord syndromes related to fractures, dislocations, blunt trauma (central cord syndrome). 3. Ages: 18 to 65

4. Males - including those involved in active military duty.

5. Females - of child-bearing potential who have a negative pregnancy test (hCG urine)

within 72 hours of informed consent. Pregnant women will be excluded from the study. Exclusion Criteria: 1. Complete cord transection, severe head injury, coma, or other disease of the CNS, and spinal injury diagnosed later than 24 hours. 2. Pregnant women (minocycline can cause fetal harm) and children. 3. Lower extremity fractures, mildly reduced consciousness and frail cognitive status will not be considered for exclusion. 4. Patients who will not be enrolled will be listed and reason for non inclusion will be recorded. Spinal tumors: Inclusion Criteria: 1. Intrathecal extramedullary tumors, vertebral metastases or primary vertebral tumors causing cord compression with or without incomplete cord syndrome. Exclusion criteria: 1. Intramedullary tumors or tumors causing complete cord syndrome

-

Locations and Contacts

Benjamim Drenger, Prof., Email: drenger@ekmd.huji.ac.il

Hadassah Medical Organization, Jerusalem, Israel; Not yet recruiting
Additional Information

Starting date: May 2013
Last updated: March 15, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017